An integrated meta-analysis of four studies (n = 574) demonstrated that the occurrence of serious AEs did not differ significantly between adults with ITP treated with SYK and/or BTK inhibitors and those receiving placebo (OR 0.87; 95%CI: 0.57 – 1.31, p=0.50, I2 = 0%, random-effect model) (Figure 3C) (Table 3). Here, SYK is linked to autoimmune thrombocytopenic purpura.